Publications by authors named "B Zauli"
Article Synopsis
- Many people living with HIV (PLHIV) have poor knowledge about sexually transmitted infections (STIs) and HIV transmission, which can negatively affect their quality of life.
- A study was conducted with 200 PLHIV in Italy using an anonymous questionnaire to assess their understanding of HIV and STIs, with a focus on disclosure and the concept of undetectable = untransmittable (U=U).
- Results showed that only 25% of participants knew how HIV is transmitted, and while a majority disclosed their status to healthcare providers and friends, there are significant gaps in understanding U=U, highlighting the need for better education to reduce stigma and improve life quality.
Article Synopsis
- A new prognostic model for COVID-19 progression was developed to include vaccination status and early treatment, which were missing from previous scores.
- The study analyzed data from 1,145 patients in Sassari, revealing that older age, comorbidities, and lack of vaccination were linked to disease progression, where 29.3% of patients required supplemental oxygen.
- Multivariate analysis identified key risk factors for progression and created an easy-to-use scoring system based on various clinical and demographic variables, enhancing the ability to predict patient outcomes.
Article Synopsis
- The study aimed to assess how many people living with HIV (PLWH) are eligible for a long-acting injectable treatment (CAB+RPV) and compare their characteristics to those who are ineligible.
- Conducted with 514 participants, the research found that 44.5% were eligible for the CAB+RPV regimen, with eligible individuals generally having fewer treatment backgrounds and being more likely to be on current NNRTIs.
- The findings suggest that less than half of virologically suppressed PLWH in the cohort qualify for the treatment and that eligible individuals tend to have simpler treatment histories.
Article Synopsis
- * While 82.7% of diagnosed individuals started therapy, only about 55.7% adhered to follow-up care; concerningly, linkages to treatment for HBV and HIV stood at only 51.5% and 30.8%, respectively.
- * Factors such as having symptoms and previous STIs increase the likelihood of new infections, with transgender females facing higher risks, highlighting the necessity for targeted health interventions to support this vulnerable population.
Dalbavancin is a novel long-acting semi-synthetic lipoglycopeptide. It is licensed for acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci. Many studies on dalbavancin alternative use in clinical practice have been published recently, including osteomyelitis, prosthetic joint infections (PJIs), and infective endocarditis (IE).
View Article and Find Full Text PDF